Department of Public Health, College of Health Sciences, QU Health, Qatar University, P.O. Box, 2713, Doha, Qatar.
Michigan Medical Advantage Group, Ann Arbor, MI, USA.
BMC Cancer. 2019 Aug 14;19(1):807. doi: 10.1186/s12885-019-5985-6.
The association between oral contraceptive (OC) use and long-term mortality remains uncertain and previous studies have reported conflicting findings. We aim to assess the long-term impact of OC use on all-cause and cancer-specific mortality.
Out of 49,259 participants, we analysed data on 2120 (4.3%) women diagnosed with first primary breast cancer between 1993 and 2012, in the Swedish Women's Lifestyle and Health Study. Kaplan-Meier plots were used to graph the hazard of mortality in association with oral contraceptives use, stage of disease and hormone receptors status at diagnosis. Cox proportional hazard model were used to estimate hazard ratios (HR) between OC use and all-cause mortality. The same association was studied for breast cancer-specific mortality by modelling the log cumulative mortality risk, adjusting for clinical stage at diagnosis, hormone receptor status, body mass index and smoking.
Among 2120 women with breast cancer, 1268 (84%) reported ever use of OC and 254 died within 10 years of diagnosis. The risk of death for OC ever-users relative to never-users was: HR = 1.13 (95% CI: 0.66-1.94) for all-cause mortality and HR = 1.29 (95% CI: 0.53-3.18) for breast cancer-specific mortality. A high percentage of women (42.9%) were diagnosed at early stage disease (stage I).
Among women with primary breast cancer, OC ever-users compared to never- users did not have a higher all-cause or breast cancer specific-mortality, after the adjustment of risk factors.
口服避孕药(OC)的使用与长期死亡率之间的关联仍不确定,先前的研究结果存在矛盾。我们旨在评估 OC 使用对全因死亡率和癌症特异性死亡率的长期影响。
在瑞典女性生活方式和健康研究中,我们分析了 1993 年至 2012 年间诊断出的 2120 名(4.3%)患有原发性乳腺癌的女性的 49259 名参与者的数据。Kaplan-Meier 图用于描绘与口服避孕药使用、疾病分期以及诊断时激素受体状态相关的死亡率风险。Cox 比例风险模型用于估计 OC 使用与全因死亡率之间的风险比(HR)。通过对诊断时的临床分期、激素受体状态、体重指数和吸烟进行调整,对乳腺癌特异性死亡率进行建模,研究了 OC 使用与乳腺癌特异性死亡率之间的关联。
在 2120 名患有乳腺癌的女性中,有 1268 名(84%)报告曾使用过 OC,其中 254 名在诊断后 10 年内死亡。OC 使用者相对于未使用者的死亡风险为:全因死亡率的 HR=1.13(95%CI:0.66-1.94),乳腺癌特异性死亡率的 HR=1.29(95%CI:0.53-3.18)。很大比例的女性(42.9%)被诊断为早期疾病(I 期)。
在患有原发性乳腺癌的女性中,OC 使用者与从未使用者相比,在调整了风险因素后,全因死亡率或乳腺癌特异性死亡率并没有更高。